Wall Street analysts expect Vertex Pharmaceuticals (VRTX) to post quarterly earnings of $4.10 per share in its upcoming report, which indicates a year-over-year increase of 34.4$2.56 billion, up 7.8% from the year-ago quarter. The current level reflects an upward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Bef ...